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Human Immunodeﬁciency Virus Treatment–Induced
Adipose Tissue Pathology and Lipoatrophy:
Prevalence and Metabolic Consequences
Emma Hammond, Elizabeth McKinnon, and David Nolan
Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Western Australia
Background. Lipoatrophy and metabolic complications of treatment of human immunodeﬁciency virus (HIV)
infection may share common associations with adipose tissue pathology and inﬂammation. To investigate these
relationships, we undertook a large-scale study of adipose tissue, body composition, and metabolic outcomes
among HIV-infected adult men at a tertiary hospital HIV cohort during the period 2001–2007.
Methods. Assessments included adipose biopsies (np211) for investigation of adipocyte mitochondrial DNA
content, adipocytokine expression, and adipose macrophage content; and whole-body dual-energy X-ray absorp-
tiometry (DEXA) scans (np225) for objective body composition changes; 138 individuals contributedbothbiopsy
and DEXA data.
Results. Compared with 78 treatment-naive control subjects, 98 zidovudine recipients (48%) and 49 stavudine
recipients (67%) had leg fat measures !10% threshold value. Adipose samples associated with current stavudine
or zidovudine (np99) revealed signiﬁcant adipocyte mitochondrial DNA depletion, adipose tissue macrophage
inﬁltration, and elevated proinﬂammatory cytokine levels, compared with samples from control subjects and
nonthymidine nucleoside reverse-transcriptase inhibitor (NRTI) recipients (all P!.05). Improvements in adipose
pathology after NRTI switching (np21 longitudinal samples) correlated with increased preswitch adipose inﬂam-
mation and less severe fat loss (both P!.05). Elevated ratios of total to high-density lipoprotein cholesterol levels
and Homeostatic Metabolic Assessment scores correlated independently with lipoatrophy severity (P!.05) and
increased body mass index (P!.05) in thymidine NRTI-experienced individuals. No effect of demographic or
HIV-related variables, or HIV protease inhibitor therapy exposure was detected.
Conclusions. Adipose tissue pathology and lipoatrophic fat loss are highly prevalent among recipients of
stavudine- or zidovudine-based HIV treatment and are associated with adverse metabolic outcomes. Restoring
adipose tissue health appears to be an important issue in the long-term treatment of this patient population.
A syndrome of progressivelipoatrophyaffectinghuman
immunodeﬁciency virus (HIV)–infected patients was
ﬁrst identiﬁed 110 years ago [1, 2], coinciding with the
introduction of highly active antiretroviral treatment
(HAART). Although initially ascribed to HIV protease
inhibitor treatment [1], clinical studies from the early
HAART era indicated that use of stavudine and zidovu-
dine nucleoside reverse-transcriptase inhibitors (NRTIs)
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was a dominant risk factor [2–4]. Subsequent clinical
trials [5, 6] and cohort studies [7, 8] have established
strong associations between stavudine treatmentandrisk
of lipoatrophy, whereas zidovudine treatment is associ-
ated with the syndrome to a lesser extent [2–4, 9]. These
ﬁndings are consistent with studies of adipose biopsy
samples that identiﬁed speciﬁc effects of stavudine and
zidovudine on mitochondrial DNA content, mitochon-
drial function, and adipose pathology [10–13].
There has been a signiﬁcant reduction in lipoatrophy
incidence in recent years associated with decreasing use
of stavudine and zidovudine, although the persistent
nature of established lipoatrophy, with only partial re-
covery after switching or removing NRTI drugs [14,
15], has ensured that the syndrome remains highly
prevalent. For example, 49% of HIV-infected men in
the Fat Redistribution and Metabolic Change in HIV
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Infection (FRAM) study had measures of leg subcutaneous fat
mass below the lowest 10% of control values [7], whereas 26%
of cohort participants in the Data collection on Adverse events
of anti-HIV Drugs (D:A:D) study had subjective evidence of
lipodystrophy [16]. Given that loss of ∼30% subcutaneous fat
volume is required before lipoatrophy becomes clinically ap-
parent [17], these data suggest a large burden of adipose tissue
pathology among treatment-experienced HIV-infected patients
[11].
Lipoatrophy can be stigmatizingandhasbeenassociatedwith
depression and reduced quality of life [18, 19]. However, it is
also apparent that lipoatrophy is associated with endocrinedys-
function (reviewed in [20]), in keeping with the pivotal role
of adipose tissue in regulating whole-body metabolism [21].
Thus, lipoatrophy has been independently associated with el-
evated cardiovascular disease risk [22], incident diabetes mel-
litus [23], and pro-atherogenic dyslipidemia [24]; this suggests
that lipoatrophy and obesity may share common pathological
features and adverse metabolic consequences, despite their ob-
vious phenotypic differences.
In this study, we examined relationships between HIV ther-
apy, adipose tissue pathology, mitochondrial DNA depletion,
objectively assessed fat loss, and metabolic outcomes among
participants in the Western Australian HIV Cohort study
SUBJECTS AND METHODS
Study design. Adult male participants in the Western Aus-
tralian HIV Cohort study were enrolled in thisnonrandomized,
observational study during the period 2001–2007. Multiple bi-
opsy samples were contributed from a total of 58 participants.
Patients were sampled longitudinally either (1) at the time of
being antiretroviral therapy [ART] naive and subsequently after
receiving thymidine NRTI (np15), (2) at the time of being
ART naive and subsequently after receiving nonthymidine
NRTI (np15), or (3) before and after switching NRTI therapy
(np28). Overall, 211 biopsy specimens werecollectedforanal-
ysis (48 samples from ART-naı ¨ve patients, 105 from thymidine
NRTI recipients, 17 from patients who initially received non-
thymidine NRTI therapy, and 41 from recipients of nonthymi-
dine NRTIs with a prior history of thymidine NRTI therapy).
We used whole-body dual-energy x-ray absorptiometry
(DEXA) scan measurements of body composition among 78
treatment-naive participants, as well as 98 patients treated ex-
clusively with zidovudine-based HAART and 49 treated with
stavudine-based HAART. Relationships between fat loss and
adipose tissue mitochondrial DNA depletion were further in-
vestigated in a subset of patients with both biopsy and DEXA
data (39 ART-naive patients, 64 zidovudine-treated patients,
and 33 stavudine-treated patients).
Study participants continued to receive routine clinical care
with regular clinic reviews every 3 months, and study partic-
ipation did not inﬂuence HIV treatment decisions. Clinical and
laboratory data routinely collected included age, race, weight,
body mass index (BMI), T cell subset levels, and history of
antiviral drug use. All study procedures were approved by the
Royal Perth Hospital Bioethics Committee, and subjects pro-
vided written consent.
Body composition assessments. Whole-body DEXA scans
were performed on a QDR-4500A scanner (Hologic). To eval-
uate lipoatrophy, we focused on an objective measure of pe-
ripheral subcutaneous fat (leg fat as a percentage of leg mass)
normalized to body mass index, as described elsewhere [12,
29]. We also evaluated leg fat mass (in kilograms) and an al-
ternative measurement used in the analysis of theFRAMcohort
[7], in which the percentage of leg fat was normalized only to
height (in meters) squared.
Subcutaneous adipose tissue biopsies and adipocyte mito-
chondrial DNA analysis. Biopsy specimens were obtained
from thesuprailiacregion,andmitochondrialandnuclearDNA
copy numbers were measured by real-time polymerase chain
reaction, using Taqman chemistry on the 7900 sequence de-
tection system platform (Applied Biosystems), as previously
described [11, 25]. This assay has been validated in an inter-
national quality assurance study [26].
Tissue adipokine analysis. Frozen tissue (50–100 mg) was
manually homogenized with 200ml of phosphate bufferedsaline
containing protease inhibitors. Homogenates were centrifuged
at 25,160g (Allegra 25R) for 10 minutes at 4 degrees. Samples
were stored at 80 C prior to quantitation of levels of adi-
ponectin (dilution of 0.02 of tissue homogenate) and IL-8 and
leptin (neat homogenate) by LINCOplex kit immunoassay(hu-
man adipocyte kit, HADCYT-61K) on a luminex 200 platform
(Luminex, Australia). Quantiﬁcation of each protein was per-
formed using standard curves generated in each run. As mea-
sures of homogenate quantity could not be standardized across
individuals adipokine results were expressed as ratios of one to
another.
Adipose tissue immunostaining. Tissue histology was as-
sessed in parafﬁn-processed biopsy sections of 4-mm thickness.
The number of macrophages (expressing CD68 or MAC387
antigens) and the expression of cytokines (interleukin [IL]–6,
IL-8, IL-12, IL-18, tumor necrosis factor, and interferon-g)
were evaluated using standard immunohistochemical tech-
niques. Primary antibody was applied for 1 h. Details of the
source and individual concentrations of antibodies used are
available from the authors. A Chemicon kit (catalogue number
Det-HP-1000) that employed an initial blocking step with goat
serum and carrier protein and a 2-step streptavidin-horserad-
ish peroxidase combination were used for immunohistochem-
istry, prior to colormetric detection by 3,3
 -diaminobenzidine
tetrahydrochloride.
Quantitative assessment of cytokine expression in the cy-
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Table 1. Last Available Body Composition Data for Adult Human Immunodeﬁciency Virus–Infected Men Who
Were Antiretroviral (ART) Naive or Who Were Treated Exclusively with Zidovudine (AZT) or Stavudine (d4T)
Characteristic
ART-naive
participants
Zidovudine
recipients
Stavudine
recipients
No. of DEXA scans 78 98 49
Duration current backbone NRTI therapy, months … 45 (25–73) 22 (15–40)
Lamivudine as second NRTI agent, percentage of patients … 94 78
Percentage of protease inhibitor recipients … 34 69
Age at DEXA scan, years 42 (32–50) 43 (39–53) 40 (37–46)
Age at time of commencement of ART, years … 38 (33–46) 37 (35–44)
CD4 T cell count, cells/mL
At time of DEXA scan 299 (146–508) 556 (301–796) 550 (342–703)
At commencement of ART … 318 (160–478) 320 (148–435)
Percentage of patients with undetectable viral load 3 75 59
Leg fat level, kg 4.8 (3.6–6.7) 3.6 (2.8–4.9)
a 2.7 (2.1–3.8)
a
Leg fat percentage/BMI 0.84 (0.7–1.0) 0.65 (0.5–0.8)
a 0.55 (0.4–0.8)
a
BMI 23.9 (20.8–26.5) 24.2 (22.0–26.4) 22.0 (20.2–24.4)
Trunk fat, kg 6.5 (4.2–10.3) 7.5 (4.9–10.3) 5.5 (3.8–8.4)
Triglyceride level, mmol/L 1.4 (0.9–1.9) 1.5 (1.0–2.6) 1.9 (1.2–2.8)
b
Lactate level, mmol/L 1.3 (1.0–1.8) 1.5 (1.2–2.0) 1.4 (1.2–1.9)
Total cholesterol level, mmol/L 4.1 (3.5–7.2) 4.9 (4.3–5.6)
a 5.5 (4.6–6.3)
a
LDL cholesterol level, mmol/L 2.4 (1.7–3.2) 2.7 (2.2–3.3)
c 3.1 (2.4–3.9)
a
HDL cholesterol level, mmol/L 1.0 (0.8–1.1) 1.1 (0.9–1.4)
a 1.1 (0.9–1.4)
b
Ratio of total to HDL cholesterol level 4.1 (3.5–5.6) 4.3 (3.4–5.4) 4.7 (3.7–5.7)
HOMA score 1.6 (1.1–3.2) 2.1 (1.2–4.2) 1.7 (1.1–3.0)
NOTE. Data are median (interquartile range), unless otherwise indicated. BMI, body mass index (calculated as weight in kilograms
divided by the square of height in meters); DEXA, dual-energy x-ray absorptiometry; HDL, high-density lipoprotein; LDL, low-density
lipoprotein; NRTI, nucleoside reverse-transcriptase inhibitor.
a P!.001, for comparisons with the ART-naive group, by t test with transformation of data (as appropriate).
b P!.01, for comparisons with the ART-naive group, by t test with transformation of data (as appropriate).
c P!.05, for comparisons with the ART-naive group, by t test with transformation of data (as appropriate).
toplasm of adipocytes was evaluated under light microscopy
with a 7-point staining score that took both intensityandextent
of immunoreactivity into account. The derived score for each
case ranged from 0 (negative staining) to 3 (maximum staining
intensity detected in 100% of cells). Macrophage count was
performed per 40 ﬁeld of view, and the mean value for 2
ﬁelds was recorded.
All metabolic measures in plasma samples were obtained by
Pathwest Laboratory (Perth, Western Australia) using standard
methods. For analyses of insulin resistance, Homeostatic Met-
abolic Assessment (HOMA) scores were calculated as follows:
[fasting serum insulin level (in mU/L)fasting plasma glucose
level (mmol/L)]/22.5.
Statistical analysis. Simple correlations were summarized
using the Spearman correlation coefﬁcient, and sample sub-
groups were compared by t tests; additional assessments of
association were undertaken in a linear regression framework,
with log-transformation of variables as appropriate. Mixed-
effects models were used for analyses with multiple measures
per person. Analyses were performed using S-Plus, version 8.1
(Tibco).
RESULTS
The characteristics of the body composition (DEXA) dataset
are described in Table 1, including demographic, clinical, and
ART-related variables. The adipose tissue biopsy dataset, in-
cluding the distribution of HIV treatment regimens at the time
of biopsy collection, is shown in Table 2. Biopsy samples were
used for analyses of adipose tissue mitochondrial DNA deple-
tion (np211), adipose tissue morphology (np68), and mea-
surements of tissue cytokines by histochemistry (np69) and
protein immunoassay (np67), to assess the effects of starting
or altering HIV therapy on these variables.
Body Composition and Adipose Tissue Pathology among ART-
Naive Subjects
We ﬁrst sought to establish normative values for ART-naive
study participants, to examine potential effects of HIV disease
status and demographic variables on body composition and
adipose tissue pathology.
Proportional fat distribution. This analysis considered 78
male ART-naive individuals with a median age of 42 years,
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Table 2. Characteristics of the Adipose Tissue Biopsy Dataset for 211 Biopsy Specimens
Characteristic
ART-naive
patients
Thymidine
NRTI-naive
patients
a
Zidovudine
recipients
Stavudine
recipients
Thymidine-
experienced
patients
a
No. of biopsy samples 49 16
b 66 33 39
c
Duration of current backbone NRTI
therapy, months … 5.9 (5.3–6.5) 40.6 (10.5–61.8) 35.8 (10.6–48.0) 7.0 (5.5–11.4)
Lamivudine as second NRTI agent,
percentage of patients … 100 98 79 95
Percentage of protease inhibitor recipients … 44 39 45 23
Age at time of biopsy, years 41 (34–50) 44 (40–47) 47 (39–53)
d 44 (38–52) 52 (42–57)
e
CD4 T cell count, cells/mL
At time of biopsy 345 (160–493) 614 (504–804) 624 (496–780)
e 578 (437–809)
e 609 (480–759)
e
At commencement of ART … 418 (238–553) 359 (180–475) 357 (304–480) 345 (154–530)
Percentage of patients with an undetectable
viral load 4 94 85 76 90
Adipocyte mitochondrial DNA level,
copies/cell 882 (609–1653) 967 (676–1601) 513 (349–954)
e 263 (180–376)
e 710 (337–1098)
NOTE. Data are median (interquartile range), unless otherwise indicated. ART, antiretroviral therapy; BMI, body mass index (calculated as weight in kilograms
divided by the square of height in meters); NRTI, nucleoside reverse-transcriptase inhibitor.
a Patients received abacavir and/or tenofovir.
b Biopsy samples were available for 15 abacavir recipients and 2 tenofovir recipients (1 patient received abacavir and tenofovir concurrently).
c Biopsy samples were available for 33 abacavir recipients and 8 tenofovir recipients (2 patients received abacavir and tenofovir concurrently).
d P!.05, for comparisons with the ART-naive group, by t test with transformation of data (as appropriate).
e P!.001, for comparisons with the ART-naive group, by t test with transformation of data (as appropriate).
median current CD4
+ T cell count of 299 cells/mL,andamedian
current plasma HIV RNA level of 4.9 log10 copies/mL (Table
1). In this group, BMI-adjusted leg fat percentages were log-
normally distributed, with a median value of0.84.Thismeasure
was not associated with BMI (Pp.8), age (Pp.3), CD4
+ cell
count (Pp.5), or HIV load (Pp.4). In contrast, both leg fat
mass and an alternative measure of fat distribution, percentage
of leg fat normalized by height-squared, were found to be sig-
niﬁcantly associated with BMI (Rp0.72 and Rp0.55, re-
spectively; P!.001), CD4
+ T cell count (Rp0.36 and Rp0.23,
respectively; P!.05) and HIV RNA level (Rp0.33 and R
p0.24, respectively; P!.04). For this reason, subsequent
analyses focused on BMI-normalized percentage of leg fat.
Adipocyte mitochondrial DNA content. Forty-six evalua-
ble biopsy specimens collected before commencement of HIV
therapy provided a median adipocyte mitochondrial DNA con-
tent of 882 copies/cell (Table 2). There was no detectable effect
of age (Pp.7), CD4
+ T cell count (Pp.7), or HIV RNA level
(Pp.4) on this variable, and there was also no evidence of an
association between mitochondrial DNA content and fat dis-
tribution in 38 subjects with data on both measures available
(Pp.5).
Adipose tissue pathologyandcytokineexpression. Adipose
tissue macrophage content (np20) and analyses of adipocy-
tokine expression (np13) among individuals who were un-
treated for HIV infection were used as baseline comparator for
treatment effects. Blinded evaluation of adipose samples by an
experienced pathologist [25] demonstrated no evidence of
pathological change.
Plasma lipids and insulin resistance. Results of fasting
metabolic assessments for the ART-naive group are provided
in Table 1. Measures of BMI-adjusted leg fat correlated mar-
ginally with HOMA scores (Rp0.23; Pp.08) but not with
the available corresponding measures of plasma lipids: levels
of triglycerides (Pp0.4), lactates (Pp.8), total cholesterol
(Pp.9), low-density lipoprotein cholesterol (Pp.3), or high-
density lipoprotein (HDL) cholesterol (P1.9).
Effects of Thymidine NRTI-Based Regimens on Body
Composition and Adipose Tissue
Proportional fat distribution and cumulative thymidineNRTI
therapy. Here we considered 147 male West Australian HIV
cohort participants who had been treated exclusively with sta-
vudine (np49; median duration of exposure, 22 months) or
zidovudine (np98; median duration of exposure, 45 months)
(Table 1). In this group, the last available on-treatment leg fat
measures were considerably lower than those in ART-naive
control subjects (P!.001) for both zidovudine-treated and sta-
vudine-treated patients, although there was little difference in
trunk fat or overall BMI across these groups (Table 1). Com-
paring these results to the ART-naive population, 48% of zi-
dovudine-treated and 67% of stavudine-treated patients had
values less than the ﬁrst decile of the naive group (Figure 1A).
More severe lipoatrophy correlated with cumulative thymi-
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Figure 1. Comparisons of proportional fat distribution (A) and adipocyte mitochondrial DNA content (B), according to treatment group. In each plot,
the cutoff value for the lowest decile in the control group (antiretroviral therapy–naive patients) group is shown, with the proportion of values below
this cutoff value indicated for each group. ABV, abacavir; AZT, zidovudine; BMI, body mass index (calculated as weight in kilograms divided by the
square of height in meters); d4T, stavudine; TDF, tenofovir.
dine NRTI exposure (Rp0.27; P!.001), higher CD4 T cell
count (Rp0.20; Pp.02), and older age (Rp0.18; Pp.03),
whereas no detectable association was observed with BMI (R
p0.12; Pp.1) or cumulative protease inhibitor exposure (R
p0.14; Pp.09). With use of longitudinal models that in-
cluded all available body composition measurements (496
DEXA scans), we found cumulative zidovudine and stavudine
exposure to be the dominant predictor of leg fat percentage
(P!.001), even with adjustment for CD4 T cell count (Pp
.09), age (Pp0.3), HAART component (for cumulative pro-
tease inhibitor exposure, Pp.1), or BMI (P1.9). This asso-
ciation between cumulative thymidine NRTI exposure and re-
duced BMI-adjusted leg fat percentage was also evident in the
adipose biopsy dataset (Rp0.55; P!.001).
Adipocyte mitochondrial DNA content. Median adipocyte
mitochondrial DNA content was reduced by 44% with sta-
vudine use(np32;P!.001)and by24%withzidovudinetreat-
ment (np64; P!.001) (Figure 1B). These effects were evident
within 2–12 months (stavudine, 10 patients P!.001; zidovu-
dine, 12 patients [Pp.04]), during which period leg fat mea-
sures remained stable in the stavudine group (Pp.4) and in-
creased marginally in the zidovudine group (Pp.05), as
expected [6, 7]. Levels of mitochondrial (mt) DNA remained
consistently low thereafter (P!.009), with no signiﬁcant trend
associated with longer times on treatment (for 12–60 months,
12 stavudine and 27 zidovudine recipients; for 160 months, 11
stavudine and 27 zidovudine recipients) (Figure 2).
No signiﬁcant independent effect of HIV protease inhibitor
versus NNRTI therapy was observed; in particular, regimens
containing efavirenz (np11) and lopinavir/ritonavir (np18)
were very comparable (Pp.7). Furthermore, the on-treatment
differences were not associated with pretreatment CD4 cell
count (Pp.4), HIV load (Pp.4), or BMI (Pp.2).
Effects on adipose tissue. This analysis revealedanevolving
pattern of adipose tissue pathology associated with thymidine
NRTI treatment characterized by increased tissue macrophage
count and proinﬂammatory cytokine staining (Figure 2). Loss
of leg fat and severity of mtDNA depletion correlated inde-
pendently with both adipose tissue macrophage count (leg fat,
Rp0.65 and P!0001; mtDNA, Rp0.51 and Pp.004),
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Figure 2. Effects of nucleoside reverse-transcriptase inhibitor treatment on markers of adipose tissue pathology. Mean values  2 standard errors
(from a linear mixed effects model) are plotted for each marker. P values are for comparisons with antiretroviral treatment–naive control subjects.
ABV, abacavir; AZT, zidovudine; BMI, body mass index (calculated as weight in kilograms divided by the square of height in meters); d4T, stavudine;
IL-8, interleukin-8; TDF, tenofovir.
and pro-inﬂammatory cytokine score (normalized percentage
of leg fat, Rp0.48 and Pp.005; mtDNA, Rp0.59 and
P!.001). Moreover, signiﬁcant changes were observed within
18 months after initiation of therapy (a 112% increase in mac-
rophage count [Pp.02] and a 53% increase in mean cytokine
score [Pp.009]) in 11 patients with both pretreatment and
on-treatment measures available.Increasedadiposetissueratios
of IL-8 to adiponectin level and of IL-8 to leptin level were
also associated with cumulative thymidine exposure (Figure 2)
and correlated with lipoatrophy severity (normalized percent-
age of leg fat, Rp0.44 [Pp.04] and Rp0.54 [Pp.009],
respectively) (Figure 3).
Effects on plasma lipids and insulin resistance. Here, we
used available database records of fasting lipid levels for the
104 participants treated exclusively with zidovudine (np69)
or with stavudine (np35). As shown in Table 1, the overall
effect of thymidine NRTI treatment on these fasting metabolic
variables was relatively modest, with nonsigniﬁcant increases
in the ratio of total to HDL cholesterol level and the HOMA
score measure of insulin resistance. However, additional anal-
ysis revealed signiﬁcant associations between lipoatrophy se-
verity and increased levels of serum lactate (Rp0.25; Pp
.01) and triglycerides (Rp0.23; Pp.02), lower HDL choles-
terol levels (Rp0.32; Pp.001), and increased HOMA scores
(Rp0.42; Pp.002). Multivariate longitudinal analyses of all
available measures of these patients found that lower HDL cho-
lesterol levels and higher HOMA scores remainedassociatedwith
both decreased leg fat (either normalized or kilograms) and in-
creased BMI (in respective joint models of leg fat level [in ki-
lograms] and BMI, the P values for HDL cholesterol were .002
and .001, and the P values for HOMA score were. 01 and !.001).
Effects of Nonthymidine NRTI Therapy: Initiating and Switching
Therapy
There was no evidence of adipocyte mtDNA depletion among
15 patients initiating abacavir-based therapy or 2 patients ini-
tiating tenofovir-based therapy (median duration of exposure,
5.9 months; IQR, 5.3–6.5 months; Pp.8, compared with treat-
ment-naive participants), nor was there evidence of adipose
tissue pathology (Figure 2). To consider nonthymidine NRTI
treatment in the context of NRTI switching strategies,39biopsy
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Figure 3. Relationship of lipoatrophy with markers of inﬂammation in tissue of thymidine-experienced patients. Spearman correlations are noted
for patients who were currently receiving a thymidine-based regimen (+) or switched to an abacavir- or tenofovir-based regimen ( ). BMI, body mass
index (calculated as weight in kilograms divided by the square of height in meters); IL-8, interleukin-8.
samples were obtained from patients who had previously re-
ceived thymidine-based NRTI treatment (33 abacavir recipients
and 8 tenofovir recipients). Severity of lipoatrophyamongthese
post-switch patients correlated with cumulative prior thymi-
dine exposure (Rp0.43; P!.001) rather than total duration
of therapy (Rp0.34; Pp.04), and it remained strongly as-
sociated with ratio of IL-8 to adiponectin level (Rp0.81;
P!.001) and ratio of IL-8 to leptin level (Rp0.74; Pp.007)
but not with macrophage count or proinﬂammatory cytokine
scores.
Among 21 individuals who provided biopsy samples both
before and after switching to nonthymidine NRTI therapy
(median duration since switching, 7.0 months; IQR, 5.7–8.5
months), NRTI switching had no detectable effect on leg fat
level over the time periods considered (Pp.9). However, post-
switch mtDNA levels were signiﬁcantly higher than values dur-
ing thymidine therapy (Pp.01). Decreases in macrophage
count and proinﬂammatory cytokine scores correlated with
higher baseline values (data for 7 and 8 patients, respectively;
Pp.04 and .003, respectively), whereas decreases in the ratio
of IL-8 to adiponectin level were associated with both higher
preswitch cytokinevaluesandlessseverelegfatreductionbefore
the switch (data for 16 patients; Pp.006 and .04, respectively,
in a joint model).
DISCUSSION
This study used a large number of adipose biopsies and body
composition assessments from Western Australian HIV Cohort
participants that were collected during the period 2001–2007,
during which zidovudine- and stavudine-based treatment reg-
imens were progressively phased out of clinical practice. With
respect to this study, this has provided the opportunity to ob-
serve the long-term effects of ART choice on body composition
and metabolic outcomes.
Our ﬁndings indicate that adipose tissue pathological changes
and consequent lipoatrophic fat loss are highly prevalent among
patients treated with thymidine NRTI-based treatment regimens.
Among adult men with 112 months of exposure to these drugs,
we found that one-half of zidovudine recipients and two-thirds
of those treated with stavudine had leg fat measures less than
the lowest decile value derived from untreatedHIV-infectedcon-
trol subjects. In keeping with previous studies, we found that
lipoatrophy is associated with—and preceded by—adipocytemi-
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tochondrialDNAdepletion[10–12,25,27–29]andadiposetissue
inﬂammation accompanied by proinﬂammatory adipocytokine
changes [12, 13, 30, 31]. The morphological characteristics of
this adipose tissue pathology are consistent with the “crown-like
structures” observed in white adipose tissue samples obtained
fromobesehumansandanimals,inwhichactivatedmacrophages
form syncytia around necrotic adipocytes [32]. These are repro-
duced abundantly in lipoatrophic tissue specimens [25, 27], im-
plying a common pathological pathway by which these condi-
tions may associate with chronic adipose tissue inﬂammation
and the “metabolic syndrome” phenotype. This is in keeping
with ﬁndings in this and other studies that lipoatrophy (pref-
erential subcutaneous fat loss) and increased BMI (overall adi-
posity) both contribute to risk of insulin resistance and elevated
ratio of total to HDL cholesterol [7, 24, 33].
The inﬂuence of adipose tissue mitochondrial toxicity on
whole-body metabolism is of interest in this context, given that
the predominant role of adipose tissue is to store (rather than
use) energy resources. A previous study involving healthy sub-
jects [34] revealed striking correlations between adipocyte
mtDNA copy number and adipose lipogenic activity over a
range of mitochondrial DNA values entirely concordant with
HIV-infected control subjects in this study. It is therefore plau-
sible that pathological adipocyte mtDNA depletion associated
with thymidine NRTI treatment induces not only widespread
cell death and loss of fat mass, but also persistent defects in
adipose tissue function that increase exposure of the liver and
skeletal muscle to fatty acids [35, 36]. This loss of adipose tissue
“fatty acid trapping” thus contributes to insulin resistance and
dyslipidemia [37, 38], even before fat loss can be demonstrated
[28, 39]. This view of lipoatrophy as an adipose-speciﬁc mi-
tochondrial toxicity associated with both lethal and sublethal
cellular injury and loss of adipose endocrine function is con-
sistent with a model of disease pathogenesis that was initially
proposed in 2001 [40].
These ﬁndings indicate that persistent adipose tissue pa-
thology needs to be considered as a risk factor for metabolic
complications. This issue has been addressed in recent guide-
lines for the prevention and management of metabolic diseases
in HIV-infected persons [41] that recommend regular moni-
toring of fasting metabolic status and preemptive switching of
thymidine NRTI–based therapy when possible. This policy is
supported by our data indicating that the beneﬁts of NRTI
switching appear to be greatest in those with evidence of active
adipose tissue inﬂammation (highly suggestive of ongoing adi-
pocyte cell death [32]), but who have not progressed to more
severe fat loss. In a broader sense, recognition of a prominent
role for adipocyte death [32, 42] and abnormal adipose tissue
morphology and function [43] in the pathogenesis of obesity-
associated metabolic complications also provides a basis for the
development of treatment strategies that may be beneﬁcial for
those affected by lipoatrophy. In this context, recent evidence
that adipocyte turnover continues throughout adult life and is
more dynamic than previously considered [43] provides hope
that the restoration of adipose tissue metabolic and cytokine
balance may also promote adipose tissue regeneration over time.
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